FDA Gives OK for mHealth Wearable to Combat Opioid Addiction
June 15, 2018
Source: mHealth Intelligence
758
The FDA recently gave the green light for mHealth wearable, Drug Relief, to help people in the process of opioid withdrawal.
The approval helps to solidify the FDA’s investment in providing digitally based therapeutics for opioid addiction as opposed to prescription drugs.
DyAnsys’ Drug Relief, a wearable that is worn around the patient’s ear, is a neurostimulation therapy that helps to relieve the symptoms of opioid withdrawal such as depression, anxiety and cravings.
Patients can wear the device for up to 5 days and are able to experience relief within an hour of starting neurostimulation.
Srini Nageshwar, CEO of DyAnsys commented in a press release "This device offers hope to those who are suffering from opioid addiction". "We are in a full-blown crisis and we need non-narcotic options and alternatives like this that can make a significant difference for individual patients and their families."
By Ddu
Copyright©2024 Ddu. All rights reserved.
Read more on
- AZ’s Farxiga Gets FDA Priority Review For Heart Failure January 8, 2020
- Global Recall of CyPass Micro-Stent by Alcon September 3, 2018
- Merck’s New Digital Diabetes Coaching to Educate and Manage Patients August 31, 2018
- UK Advertising Regulator Bans Natural Cycles’ Facebook Ad August 31, 2018
- Researchers Move Forward In Their Search for Non-Addictive Analgesic August 31, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
